Ultromics Limited articles

Ultromics will be sharing its groundbreaking AI research and innovation at the American Society of Echocardiography’s annual Scientific Sessions.

ASE’s Foundations and the Future of Cardiovascular Ultrasound sessions bring together echo professionals and enthusiasts from across forty-five countries with a selection of networking events, seminars, and workshops from the top minds in echocardiography. 

Ultromics, a pioneer in usin

Heart failure with preserved ejection fraction (HFpEF) is a multifactorial and multisystemic disorder that represents more than 50% of all heart failure cases.[1]

Epidemiologic data from the Framingham Study, an international cohort study, shows a rapid increase in the prevalence of HFpEF over the past three decades, from 41% to 56% and, conversely, a decrease in the prevalence of HFrEF from 44% to 31%. [2]

Because of its complex pathophysiology

Heart failure affects about 6.2 million Americans and is rising in prevalence. With half of these cases presenting as heart failure with preserved ejection fraction (HFpEF), it’s essential for both the medical community and the population at large to have a better understanding of its pathology. [1,2]

Knowing the differences between HFpEF and its counterpart, heart failure with reduced ejection fraction (HFrEF), including contrasts in their cellular and molecular presentations,

Heart failure with preserved ejection fraction (HFpEF) is currently affecting over half of heart failure patients. 

The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS), use the International Classification of Diseases (ICD) for coding and reporting. Data retrieved through ICD provides critical knowledge on the ex